Loading…
Bone Biologics Corporation is projected to decline to $0.7792 by 2027, a -13% move from its current price of $0.90. BBLG is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.8731 | $0.8998 | $0.9274 | -0.02% |
| Aug 6 | $0.8621 | $0.8996 | $0.9389 | -0.04% |
| Aug 7 | $0.8537 | $0.8995 | $0.9477 | -0.06% |
| Aug 8 | $0.8466 | $0.8993 | $0.9552 | -0.08% |
| Aug 9 | $0.8405 | $0.8991 | $0.9618 | -0.10% |
| Aug 10 | $0.8349 | $0.8989 | $0.9679 | -0.12% |
| Aug 11 | $0.8298 | $0.8987 | $0.9734 | -0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8298 | $0.8987 | $0.9734 | -0.14% |
| Week 2 | $0.8017 | $0.8975 | $1.00 | -0.28% |
| Week 3 | $0.7805 | $0.8963 | $1.03 | -0.42% |
| Week 4 | $0.763 | $0.895 | $1.05 | -0.55% |
| Week 5 | $0.7477 | $0.8938 | $1.07 | -0.69% |
| Week 6 | $0.734 | $0.8925 | $1.09 | -0.83% |
| Week 7 | $0.7216 | $0.8913 | $1.10 | -0.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bone Biologics Corporation is a medical device company focused on bone regeneration in spinal fusion using a recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration.
The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications.
Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Bone Biologics Corporation (BBLG) operates in Healthcare as a medical device company focusing on bone regeneration in spinal fusion using a recombinant human protein. The current price is $0.9046 and the market cap is $1.64M. The company is ranked 5461 by market position.
The current price is $0.9046 with a market cap of $1.64M, and the rank is 5461. The price outlook from the provided forecasts shows a mix of neutral and bullish signals across the years, with neutral readings in 2026–2027 and bullish momentum emerging in later years such as 2029 and beyond, culminating in stronger projected levels by 2040 and 2050.
In 2026 the forecast sits at a neutral stance with an avg price of $0.9046 and a max of $1.11, while later years show rising averages and higher max estimates, including a bullish trajectory into 2034–2035 and continued bullishness into 2040 and 2050, suggesting an increasing price trajectory over the long term.
A major floor 52.2% below — a decisive break under it would weaken the trend.
The nearest floor, 6.0% below — buyers have tended to step in here.
The nearest ceiling, 63.3% above — a clean break opens room to run.
A major ceiling 86.4% above — clearing it would confirm fresh momentum.
Key BBLG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BBLG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9194 | Sell | $0.9152 | Sell |
| MA 10 | $1.01 | Sell | $0.997 | Sell |
| MA 20 | $1.16 | Sell | $1.10 | Sell |
| MA 50 | $1.26 | Sell | $1.21 | Sell |
| MA 100 | $1.26 | Sell | $1.31 | Sell |
| MA 200 | $1.48 | Sell | $2.10 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 17.81 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -135.92 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -31.77 | Sell |
| Bollinger %B (20,2) | 0.07 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.88 | Sell |
| Awesome (5,34) | -0.34 | Sell |
| Ultimate (7,14,28) | 3.26 | Buy |
| Momentum (10) | -0.32 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.83 | Buy |
| ADX (14) | 34.10 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is generally neutral. RSI(14) is 20, indicating cautious momentum, and the SMA50 is $1.27 while the SMA200 is $1.49.
Support is listed at $0.905 and resistance at $1.47, with a 30-day price range from $0.7398 to $1.11. The stock’s implied volatility runs at about 60% annually, underscoring elevated risk and choppiness in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.846 | $0.90 | $1.11 | 0% | Neutral | |
| $0.6157 | $0.7792 | $1.05 | -13% | Neutral | |
| $0.7016 | $0.9165 | $1.28 | +2% | Neutral | |
| $0.8132 | $1.09 | $1.57 | +21% | Bullish | |
| $0.7504 | $1.03 | $1.53 | +14% | Neutral | |
| $0.7824 | $1.10 | $1.66 | +22% | Bullish | |
| $0.7434 | $1.06 | $1.65 | +18% | Neutral | |
| $0.6758 | $0.9839 | $1.55 | +9% | Neutral | |
| $0.7805 | $1.16 | $1.86 | +28% | Bullish | |
| $0.8668 | $1.31 | $2.13 | +45% | Bullish | |
| $0.9624 | $1.57 | $2.73 | +74% | Bullish | |
| $1.37 | $2.55 | $4.89 | +183% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.846 | $0.90 | $1.11 | +0.00% |
| September 2026 | $0.7548 | $0.8951 | $1.09 | -0.55% |
| October 2026 | $0.7396 | $0.8838 | $1.09 | -1.25% |
| November 2026 | $0.751 | $0.903 | $1.13 | +2.17% |
| December 2026 | $0.7321 | $0.8853 | $1.11 | -1.97% |
Click any year to see its month-by-month BBLG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BBLG is projected to trade between $0.846 and $1.11, averaging $0.90 — a potential gain of 0% from today's $0.90. Price action looks broadly range-bound.
Bone Biologics Corporation's 2027 outlook centres on $0.7792, within a $0.6157 to $1.05 range. That is -13% versus the projected 2026 average. That marks a -13% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, BBLG could reach as high as $1.28, with a base case around $0.9165 and support toward $0.7016 — roughly +2% from $0.90. Price action looks broadly range-bound.
Expect BBLG to range from $0.8132 to $1.57 through 2029. The $1.09 average target implies a +21% move from current prices. That is up +19% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The BBLG price prediction for 2030 points to an average of $1.03 (low $0.7504, high $1.53) — a potential gain of +14% on today's $0.90. Price action looks broadly range-bound.
In 2031, BBLG is projected to trade between $0.7824 and $1.66, averaging $1.10 — a potential gain of +22% from today's $0.90. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Bone Biologics Corporation's 2032 outlook centres on $1.06, within a $0.7434 to $1.65 range. That is -3% versus the projected 2031 average. That marks a +18% change versus current levels. Price action looks broadly range-bound.
By 2033, BBLG could reach as high as $1.55, with a base case around $0.9839 and support toward $0.6758 — roughly +9% from $0.90. A consolidation phase looks the most probable path here.
Expect BBLG to range from $0.7805 to $1.86 through 2034. The $1.16 average target implies a +28% move from current prices. That is up +18% on the projected 2033 average. Momentum favours further upside here.
The BBLG price prediction for 2035 points to an average of $1.31 (low $0.8668, high $2.13) — a potential gain of +45% on today's $0.90. Buyers look set to stay in control over this stretch.
In 2040, BBLG is projected to trade between $0.9624 and $2.73, averaging $1.57 — a potential gain of +74% from today's $0.90. That is up +20% on the projected 2035 average. Momentum favours further upside here.
Bone Biologics Corporation's 2050 outlook centres on $2.55, within a $1.37 to $4.89 range. That is up +63% on the projected 2040 average. That marks a +183% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in BBLG today (≈ 1,111.111111 BBLG) could be worth
$2,832.08
+$1,832.08 (+183%) by 2050 · US Dollar
Based on the average projected BBLG price of $2.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BBLGwould be worth at today's price.
$1,000 invested in BBLG on Jul 31, 2025 (≈ 357.142863 BBLG) would be worth
$321.43
-$678.57 (-67.9%) today · 0.32× · US Dollar
Based on a BBLG entry price of $2.8 vs. today's $0.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.07 | $841.12 | -15.9% |
| 1 month ago | $1.4 | $642.86 | -35.7% |
| 3 months ago | $1.31 | $685.45 | -31.5% |
| 6 months ago | $1.63 | $552.15 | -44.8% |
| 1 year ago | $2.8 | $321.43 | -67.9% |
| All time (4.8y) ago | $7,329.6 | $0.12 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BBLG forecast.
Our base-case forecast reaches $1.80 around 2050.
Implied market cap at $1.80: $3.26M
The multi-year forecast shows a mixed but upward-leaning trajectory, with notable milestones in key years. In 2030 the avg price is $1.05 and the ROI is 15.6, while sentiment remains NEUTRAL. By 2040 the avg price rises to $1.63 with an ROI of 80.2 and a BULLISH sentiment.
In 2050 the avg price is projected at $2.60 with an ROI of 187.2 and a BULLISH sentiment.
Earlier years alternate between neutral and bullish signals, such as 2029 with an avg of $1.11 and ROI of 22.2 (sentiment BULLISH) and 2031 with an avg of $1.12 and ROI of 23.8 (sentiment BULLISH). The forecast also shows substantial upside potential in 2034 (avg $1.19, ROI 31.9, sentiment BULLISH) and 2035 (avg $1.34, ROI 47.9, sentiment BULLISH).
These are estimates, not guarantees, and reflect a path where later years exhibit stronger upside potential while earlier years may show limited or negative returns. Investors should consider the range of possible outcomes and the inherent uncertainties in early-stage healthcare devices and biotech applications.
Tap a question to reveal the answer.
In 2026 the forecast shows a min price of $0.9046, an avg price of $0.9046, and a max price of $1.11, with a ROI of 0 and sentiment NEUTRAL.
Yes. The 2027 forecast shows a ROI of -12.8% with a min of $0.6223, avg $0.7889, max $1.06 and sentiment NEUTRAL.
The 2050 forecast shows a max price of $5.01, with an avg of $2.60 and a min of $1.39, and a ROI of 187.2 along with sentiment BULLISH.
Current price is $0.9046 and market cap is $1.64M.
The 30-day picture shows sentiment NEUTRAL, RSI(14) 20, SMA50 $1.27, SMA200 $1.49, support $0.905, resistance $1.47, and a 30-day range from $0.7398 to $1.11.
Bone Biologics Corporation Community Discussion
0Share your Bone Biologics Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.